Surgical management of late relapse on surveillance in patients presenting with clinical stage i testicular cancer

Kevin R. Rice, Stephen D.W. Beck, Jose A. Pedrosa, Timothy A. Masterson, Lawrence H. Einhorn, Richard S. Foster

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


Objective To determine survival outcomes in clinical stage I germ cell tumor (GCT) patients requiring retroperitoneal lymph node dissection (RPLND) for late relapse (LR) occurring while on surveillance. Methods The Indiana University Testis Cancer Database was queried from 1985 to 2013 to identify all patients who presented with clinical stage I GCT, elected surveillance, relapsed ≥2 years after initial diagnosis, and underwent RPLND in treatment of their LR. Clinical, pathologic, and treatment characteristics were reviewed. Results Twenty-eight patients met inclusion criteria. The mean age at diagnosis was 29.3 years. Testicular primary was pure seminoma in 2, intratubular germ cell neoplasia with scar in 1, nonseminomatous GCT in 24, and unknown in 1 patient. The median time from diagnosis to relapse was 48.5 months (range, 28-321 months). At relapse, serum tumor markers were elevated in 13 patients (46.4%). Nineteen patients were given cisplatin-based chemotherapy at LR. RPLND was initial management of LR in 9. At RPLND, 10, 5, and 13 patients demonstrated fibrosis, teratoma, and viable malignancy, respectively. On the last follow-up, 24 patients (85.7%) were free of disease and 4 patients (14.3%) had died of their disease. Conclusion When examining outcomes among patients undergoing RPLND at LR of GCT, it appears that patients experiencing LR on surveillance have more favorable histology and survival outcomes than previously reported for unselected patients experiencing LR.

Original languageEnglish (US)
Pages (from-to)886-891
Number of pages6
Issue number4
StatePublished - Oct 1 2014

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Surgical management of late relapse on surveillance in patients presenting with clinical stage i testicular cancer'. Together they form a unique fingerprint.

Cite this